Print Page    E-mail Page    RSS    E-mail Alerts 

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We are currently developing two product candidates under our INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary arterial hypertension (PAH) for which we intend to commence Phase 3 clinical testing in late 2015, and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), which is in Phase 2 development. Additionally, clinical testing using INOpulse for patients suffering from pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-IPF) is planned to commence in 2016.